IN2014CH00393A - - Google Patents
Info
- Publication number
- IN2014CH00393A IN2014CH00393A IN393CH2014A IN2014CH00393A IN 2014CH00393 A IN2014CH00393 A IN 2014CH00393A IN 393CH2014 A IN393CH2014 A IN 393CH2014A IN 2014CH00393 A IN2014CH00393 A IN 2014CH00393A
- Authority
- IN
- India
- Prior art keywords
- peptide
- support
- adhesive layer
- cellular immunity
- tape preparation
- Prior art date
Links
- 239000012790 adhesive layer Substances 0.000 abstract 2
- 230000007969 cellular immunity Effects 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013020798 | 2013-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CH00393A true IN2014CH00393A (zh) | 2015-04-03 |
Family
ID=50028734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN393CH2014 IN2014CH00393A (zh) | 2013-02-05 | 2014-01-29 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10195258B2 (zh) |
EP (1) | EP2762156A1 (zh) |
JP (1) | JP6512569B2 (zh) |
KR (1) | KR102050931B1 (zh) |
CN (1) | CN103961305B (zh) |
CA (1) | CA2841014A1 (zh) |
IN (1) | IN2014CH00393A (zh) |
RU (1) | RU2697443C2 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2900087C (en) | 2005-10-17 | 2024-02-13 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
EP3834836A1 (en) | 2006-04-10 | 2021-06-16 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and uses thereof |
WO2013106834A2 (en) | 2012-01-13 | 2013-07-18 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
HUE052541T2 (hu) | 2013-01-15 | 2021-05-28 | Memorial Sloan Kettering Cancer Center | Immunogén WT-1 peptidek és eljárások azok alkalmazására |
RU2687144C2 (ru) | 2013-02-05 | 2019-05-07 | Нитто Денко Корпорейшн | Композиция противораковой вакцины, содержащей пептид wt1, для трансдермального введения |
WO2016052698A1 (ja) * | 2014-10-02 | 2016-04-07 | 日東電工株式会社 | 経皮投与用ワクチン医薬組成物 |
DE102015119789A1 (de) * | 2015-11-16 | 2017-05-18 | Denso-Holding Gmbh & Co. | Korrosionsschutzzusammensetzung umfassend Polyisobutylene |
US20240024444A1 (en) * | 2020-08-07 | 2024-01-25 | Medrx Co., Ltd. | Combined Preparation |
CN114712493B (zh) * | 2022-04-29 | 2024-05-28 | 华南理工大学 | 一种疫苗递送载体及其制备方法和应用 |
WO2024088383A1 (en) * | 2022-10-28 | 2024-05-02 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-wt1/hla antibodies and uses thereof |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
CN102198266A (zh) | 1998-07-31 | 2011-09-28 | 株式会社国际癌症免疫研究所 | 基于癌抑制基因wt1的产物的癌抗原 |
IL127331A0 (en) | 1998-11-30 | 1999-09-22 | Yeda Res & Dev | Peptide-based vaccine for influenza |
RU2192884C2 (ru) | 2000-11-09 | 2002-11-20 | Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН | Вакцина для стимуляции противоопухолевого иммунитета |
US20040109869A1 (en) * | 2001-03-19 | 2004-06-10 | Iomai Corporation | Transcutaneous immunostimulation |
DE60224508T2 (de) | 2001-03-22 | 2008-12-24 | International Institute of Cancer Immunology, Inc., Suita-shi | Wti-modifiziertes peptid |
US7553494B2 (en) * | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
CN100408683C (zh) | 2002-06-12 | 2008-08-06 | 株式会社国际癌症免疫研究所 | Hla-a24限制性癌抗原肽 |
ATE442378T1 (de) | 2002-09-20 | 2009-09-15 | Int Inst Cancer Immunology Inc | Substituierte wt1-peptide |
US20050215501A1 (en) * | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
DK2071028T3 (da) | 2003-11-05 | 2012-03-05 | Int Inst Cancer Immunology Inc | HLA-DR-bindende antigenpeptid afledt af WT1 |
US8562988B2 (en) * | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
US7709458B2 (en) | 2004-03-15 | 2010-05-04 | David K. R. Karaolis | Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
PL1731605T3 (pl) | 2004-03-31 | 2010-08-31 | Int Inst Cancer Immunology Inc | Nowotworowe peptydy antygenowe pochodzące z WT1 |
DE102004049223A1 (de) | 2004-10-08 | 2006-04-20 | Johannes-Gutenberg-Universität Mainz | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung |
EP1782826A1 (en) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
JP4394724B2 (ja) | 2005-11-30 | 2010-01-06 | 株式会社癌免疫研究所 | 新規ペプチド化合物 |
JP5393144B2 (ja) | 2006-02-22 | 2014-01-22 | 株式会社癌免疫研究所 | Hla−a*3303拘束性wt1ペプチド、およびそれを含む医薬組成物 |
US20080112974A1 (en) | 2006-09-08 | 2008-05-15 | Duotol Ab | Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens |
JP4925039B2 (ja) | 2006-09-21 | 2012-04-25 | 日東電工株式会社 | 糖材料の調製方法ならびに糖材料、糖材料を含むマイクロニードルおよびマイクロニードルをそなえてなる経皮製剤 |
JP2008127277A (ja) * | 2006-11-16 | 2008-06-05 | Osaka Prefectural Hospital Organization | 免疫賦活化促進剤 |
PL2341142T3 (pl) | 2006-12-28 | 2015-04-30 | Int Inst Cancer Immunology Inc | Ograniczony za pomocą peptydu WT1 HLLA-A 1101i zawierające je kompozycje |
US20100047327A1 (en) | 2007-01-31 | 2010-02-25 | Tetsuji Kuwahara | Adjuvant for Transdermal or Transmucosal Administration and Pharmaceutical Preparation Containing the Same |
WO2009046738A1 (en) * | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
US8557779B2 (en) | 2007-12-05 | 2013-10-15 | International Institute Of Cancer Immunology, Inc. | Cancer vaccine composition |
US20110318380A1 (en) * | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
AR076349A1 (es) * | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
EP2498795B1 (en) * | 2009-10-12 | 2016-12-07 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Granulysin in immunotherapy |
ES2655031T3 (es) * | 2012-07-02 | 2018-02-16 | Sumitomo Dainippon Pharma Co., Ltd. | Preparación transdérmica de péptido antigénico del cáncer |
KR20140100415A (ko) | 2013-02-05 | 2014-08-14 | 닛토덴코 가부시키가이샤 | 경피 투여용 백신 조성물 |
RU2687144C2 (ru) | 2013-02-05 | 2019-05-07 | Нитто Денко Корпорейшн | Композиция противораковой вакцины, содержащей пептид wt1, для трансдермального введения |
JP6473292B2 (ja) | 2013-02-05 | 2019-02-20 | 日東電工株式会社 | ワクチン組成物 |
-
2014
- 2014-01-29 EP EP14000321.1A patent/EP2762156A1/en not_active Withdrawn
- 2014-01-29 CA CA2841014A patent/CA2841014A1/en not_active Abandoned
- 2014-01-29 RU RU2014102937A patent/RU2697443C2/ru not_active IP Right Cessation
- 2014-01-29 IN IN393CH2014 patent/IN2014CH00393A/en unknown
- 2014-01-29 KR KR1020140011637A patent/KR102050931B1/ko active IP Right Grant
- 2014-01-29 CN CN201410042748.8A patent/CN103961305B/zh not_active Expired - Fee Related
- 2014-01-29 JP JP2014014805A patent/JP6512569B2/ja active Active
- 2014-01-29 US US14/166,954 patent/US10195258B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10195258B2 (en) | 2019-02-05 |
CN103961305B (zh) | 2019-10-18 |
JP6512569B2 (ja) | 2019-05-15 |
CA2841014A1 (en) | 2014-08-05 |
RU2697443C2 (ru) | 2019-08-14 |
KR102050931B1 (ko) | 2019-12-02 |
JP2014169279A (ja) | 2014-09-18 |
KR20140100421A (ko) | 2014-08-14 |
CN103961305A (zh) | 2014-08-06 |
US20140220105A1 (en) | 2014-08-07 |
EP2762156A1 (en) | 2014-08-06 |
RU2014102937A (ru) | 2015-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CH00393A (zh) | ||
IN2014CH00396A (zh) | ||
IN2014CH00391A (zh) | ||
SG10201900693TA (en) | Pressure-sensitive adhesive sheet | |
HK1214786A1 (zh) | 用於實施治療,如癌症治療的控制器和柔性線圈 | |
MX2018008346A (es) | Terapia de combinación de virus oncológico e inhibidor de punto de control. | |
UY34780A (es) | Vectores virales para el tratamiento de distrofia retiniana | |
CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
MY167716A (en) | Drive device | |
IN2014CH00395A (zh) | ||
MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
MX2016003876A (es) | Métodos y aparatos para suministrar moléculas a través de capas de tejidos. | |
MX357202B (es) | Composicion de particula tipo virus. | |
EP3150202A4 (en) | Drug carrier for tumour-specific targeted drug delivery and use thereof | |
MY156697A (en) | Modified tuberculosis antigens | |
SG10201805806RA (en) | Modulation of Structured Polypeptide Specificity | |
PH12015501071A1 (en) | Combination therapy of anti-her3 antibodies | |
IN2014DN05885A (zh) | ||
MX2015016627A (es) | Vacuna para la malaria. | |
EP3661541A4 (en) | FACTOR VIII (FVIII) GENERAL THERAPY PROCEDURES | |
MY191539A (en) | Streptococcal vaccine | |
MX2015011837A (es) | Co-cristale de pirimetanil y tetracarboximida de ditiina seleccionada. | |
MX2016005285A (es) | Conjugados de somatostatina y sus analagos. | |
PH12015501854A1 (en) | Factor ix polypeptide formulations | |
MY165824A (en) | Induction Motor and Ceiling Fan Including the Same |